secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hemab Therapeutics Holdings, Inc. (COAG)
CIK:        0002114044
Form:       8-K
Filed at:   2026-05-21T11:05:12+00:00
Accession:  0001193125-26-233375
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hemab reports Q1 net loss $22.7M; completes $346.7M IPO, gets BTD for sutacimig
-------------------------------------------------------------------------------

- Net loss Q1 2026: $22.7M ($23.98/share) vs $15.3M ($16.18/share) YoY.
- Cash $163.5M at March 31; with $317.2M net IPO proceeds, runway into 2029.
- Completed IPO in May 2026: 19.26M shares at $18.00, raising $346.7M gross; now listed on Nasdaq under COAG.
- FDA granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia in March 2026.
- Preparing Phase 3 pivotal trial for sutacimig in GT expected H2 2026; data from Factor VII and VWD trials in late 2026/early 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2114044/000119312526233375/0001193125-26-233375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2114044/000119312526233375/d102408d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-233375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer